Table 4.

Ongoing Clinical Trials For IPL Therapy In DED

Study	Design	Condition	Patients (n)	Control Arm	IPL Device	Number Of IPL Sessions	Frequency	Outcomes	Concomitant Therapy
Dell et al (2018)	Interventional Randomized Single-masked	MGD	50	Sham IPL + MGX	Lumenis	4	2	TBUT; OSDI; EDS; Eyelid appearance; meiboscore; incidence of adverse events; pain during procedure; biomicroscopy	MGX
Pyacomn et al (2018)	Interventional Randomized Double masked	MGD	114	Sham IPL	E>Eye	3	1-2-6	TBUT; OSDI; LLT; meiboscore; CFS; MGE; meibum quality; TFO (6 months follow-up) ST; IL-1Ra; IL-6	Warm compression, lid scrub, non preservative ocular lubricants
Wood et al (2017)	Interventional Randomized Double-masked	Evaporative DED	14	Sham IPL	/	4	/	TBUT (4 months follow up); OSDI (7 months follow up)	/
Shen et al (2017)	Interventional randomized open label	Ocular rosacea	20	MGX	/	4	4	OSDI (4 months follow-up); pathologic microbial load (4 months follow-up); TGF-B1 (4 months follow-up)	MGX, topical anesthetic for DED
Zadock et al (2017)	Interventional randomized single-masked	MGD	24	Sham IPL + MGX	Lumenis	4	2	TBUT (10 weeks follow-up); MG secretion score; OSDI; MGYLS; TFO; meiboscore; eyelid appearance (10 weeks follow-up)	MGX
Dell et al (2015)	Interventional noncomparative	MGD	44	/	Lumenis	4	/	TBUT (3 weeks after each IPL session); CFS; MGS; SPEED; TFO; LLT; incidence of adverse events; immediate/short term skin response; subjective level of pain/discomfort	MGX

Abbreviations: TBUT, tear break-up time; OSDI, ocular surface disease index; EDS, eye dryness score; LLT, lipid layer thickness; CFS, corneal fluorescein staining; MGE, meibomian gland expressibility; TFO, tear film osmolarity; MGLYS, meibomian glands yielding liquid secretion; SPEED, standard patient evaluation of eye dryness.